Abstract:Objective:To explore the genetic mutation, clinical characteristics, diagnosis and treatment of patients with hereditary coagulation factor FⅪ deficiency.Methods:On August 10 and October 30, 2020, two patients with hereditary FⅪ deficiency who were admitted at Department of Hematology, West China Hospital of Sichuan University were selected as research subjects. Patients 1 and 2 were numbered according to visiting time. Diagnosis was made according to coagulation function test and results of gene sequencing F11 gene.Clinical observation or symptomatic treatment were performed according to clinical bleeding symptom and severity. Novel mutations were confirmed by retrieving Human Gene Mutation database (HGMD), Single Nucleotide Polymorphism Database (dbSNP) and PubMed database. Pathogenicity of the novel missense mutation was predicted by computational software of Mutation Taster, Polyphen-2, and PROVEAN. Follow-up of patients was conducted until February 28, 2021. Clinical manifestations and process of diagnosis and treatment of two patients were analyzed retrospectively. China National Knowledge Infrastructure database, Wanfang Data Knowledge Service Platform, PubMed database were searched for the same and similar case reports as F11 genetic mutation in this study.Retrieval time was from database inception to February 28, 2021. Types of genetic mutations and clinical manifestations related to patients in this study were summarized.This study meeted the requirements of the World Medical Association Declaration of Helsinki revised in 2013. Informed consent of patients was obtained from pateints. Results:① Results of medical history: patient 1, a 24 years old man, was admitted due to " hematoma after soft tissue trauma in left thigh and preoperative examination revealed coagulation dysfunction" and did not complain of significant discomfort.Patient 2, a 32 years old woman, was admitted due to " pre-pregnancy physical examination found prolonged activated partial thromboplastin time (APTT)" and complained of occasional ecchymosis.② Results of related laboratory examination: APTT, prothrombin time (PT) and FⅪ activity (FⅪ∶C) of patient 1 were 97.9 s, 11.9 s and 0.6%, while patient 2 were 95.4 s, 12.5 s, and 1.2%, respectively. ③ Results of DNA sequencing: patient 1 had a compound heterozygous missense mutation of F11 gene at c. 149G>T(p.Cys50Phe) and c. 1204C>T (p.Gln402Ter), while patient 2 had a homozygous deletion of F11 gene at c. 1058delA (p.Asn353ThrfsTer18). ④ F11 gene missense mutation at c. 149G>T(p.Cys50Phe) and deletion c. 1058delA(p.Asn353ThrfsTer18) were two novel mutations and both were pathogenic.⑤Results of treatment and follow-up: two patients received clinical observation. At end of follow-up, general condition of the patients was good. ⑥ Results of literatures review: among 10 patients reported in 6 relevant literatures, there were 1, 3, 6 patients caused by heterozygous nonsense mutation of c. 1204C>T(p.Gln402Ter), nonsense mutation of c. 1202C>T(p.Trp401Ter) adjacent to c. 1204C>T (p.Gln402Ter) and missense mutations near the position of c. 149G>T(p.Cys50Phe), respectively. Conclusions:Two novel mutations of hereditary FⅪ deficiency namely a missense mutation at c. 149G>T(p.Cys50Phe) and a deletion at c. 1058delA(p.Asn353ThrfsTer18) of F11 gene were reported in this study. Both of the two mutations related to decrease of FⅪ∶C.

catalytic domain Dominant factor XI deficiency caused by mutations in the factor XI

Dominant Factor XI Deficiency Caused by Mutations in the Factor XI Catalytic Domain.

Genetic analysis of patients with hereditary coagulation factor Ⅺ deficiency and literatures review

Novel Mutations in Congenital Factor XII Deficiency.

A Case of Factor XI Deficiency Caused by Compound Heterozygous F11 Gene Mutation

Global epidemiology of factor XI deficiency: A targeted review of the literature and foundation reports

Compound Heterozygous Nonsense Mutations Leading to Hereditary Deficiency of Coagulation Factor XI in a Chinese Pedigree

Molecular mechanisms of two novel mutations of factor XIII gene resulting in hereditary coagulation deficiency]

The Molecular Genetic Analysis of Coagulation Factor XI (FXI) Deficiency in Two Chinese Patients

Laboratory and Molecular Diagnosis of Factor XI Deficiency

Introduction to a review series on factor XI

Severe Coagulation Factor X Deficiency Caused by Two De Novel Heterozygous Missense Mutations in Factor X Gene

The effect of factor XIa on thrombin and plasmin generation, clot formation, lysis and density in coagulation factors deficiencies

[FXI Gene Mutations in Two Pedigrees of Congenital Clotting Factor XI Deficiency].

Clinical, Laboratory, and Molecular Aspects of Factor VII Deficiency

A Novel Heterozygous Point Mutation Causing Coagulation Factor XII Deficiency As the Molecular Mechanism of Fatal Thrombosis Event in a Chinese Pedigree.

Identification of Genetic Defects Underlying FXII Deficiency in Four Unrelated Chinese Patients

Clinical manifestations and mutation spectrum of 57 subjects with congenital factor XI deficiency in China

Characterization of molecular defect of 13387-9delG mutated antithrombin in inherited type I antithrombin deficiency.

Thrombosis, Bleeding, and the Promise of Factor XI(a) Inhibition ∗

Clinical, Laboratory Aspects and Management of Factor X Deficiency